首页> 外文期刊>Radiology >Transjugular intrahepatic portosystemic shunt patency and clinical outcome in patients with Budd-Chiari syndrome: covered versus uncovered stents.
【24h】

Transjugular intrahepatic portosystemic shunt patency and clinical outcome in patients with Budd-Chiari syndrome: covered versus uncovered stents.

机译:Budd-Chiari综合征患者的经颈静脉肝内门体分流通畅和临床结局:覆膜支架与未覆盖支架。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To retrospectively compare primary patency and reintervention rates, clinical outcome, and improvement in hepatic dysfunction (Child-Pugh score) in patients with Budd-Chiari syndrome treated with transjugular intrahepatic portosystemic shunt (TIPS) using bare stents or expanded polytetrafluoroethylene (PTFE)-covered stents. MATERIALS AND METHODS: Approval of study and treatment protocol and waiver of informed consent for the retrospective study were obtained from institutional review board. Informed consent was obtained from each patient before procedure. Four male and nine female consecutive patients (mean age, 35.7 years) with Budd-Chiari syndrome treated with TIPS from January 1994 to November 2003 were included. In six patients, TIPS creation was performed with bare stents (group A). After April 2001, TIPS creation was performed in seven patients with expanded PTFE-covered stent-grafts (group B). Follow-up (group A mean, 22.7 months +/- 10.53 [standard deviation]; group B mean, 23.1 months+/- 7.81) was performed at 7 days, 30 days, and 3 months and subsequently every 3 months. Liver function was evaluated every 3 months. Primary end points were 6- and 12-month TIPS patency rates. Secondary end points were reintervention rate and clinical outcome. Patency rates were estimated (Kaplan-Meier method) and compared (log-rank test). Continuous (Mann-Whitney U test) and categoric (chi(2) test) data were compared. Significant differences before and after treatment were determined (Wilcoxon test). RESULTS: Mean primary patency duration was 4.46 months +/- 3.40 in group A and 22.29 months +/- 8.15 in group B. In group B, a significant increase in primary patency rate (100% and 85.7% vs 16.7% and 0% at 6 and 12 months; P < .001, log-rank test) and a decrease in reintervention rate (0.29 +/- 0.49 vs 6.17 +/- 1.72, P < .001) were observed. Both groups had a significantly decreased Child-Pugh score; group B had a more persistent and significantly higher reduction. CONCLUSION: Expanded PTFE-covered stent-grafts significantly increased primary patency rate of TIPS in patients with Budd-Chiari syndrome, with reduced reintervention rate and prolonged clinical improvement.
机译:目的:回顾性比较经颈静脉肝内门体分流术(TIPS)使用裸露支架或扩张型聚四氟乙烯(PTFE)治疗的Budd-Chiari综合征患者的原发通畅率和再干预率,临床结局和肝功能障碍的改善(Child-Pugh评分)覆膜支架。材料与方法:研究和治疗方案的批准以及对回顾性研究的知情同意的放弃均从机构审查委员会获得。术前从每位患者获得知情同意。从1994年1月至2003年11月,接受TIPS治疗的4例男性和9例女性连续Budd-Chiari综合征患者(平均年龄35.7岁)。在六名患者中,使用裸露的支架(A组)进行了TIPS创建。 2001年4月之后,对7名扩张了PTFE覆膜支架的患者(B组)进行了TIPS创建。随访(A组平均22.7个月+/- 10.53 [标准差]; B组平均23.1个月+/- 7.81)在7天,30天和3个月进行,随后每3个月进行一次。每3个月评估肝功能。主要终点是6个月和12个月的TIPS通畅率。次要终点是再干预率和临床结局。估计通畅率(Kaplan-Meier方法)并进行比较(对数秩检验)。比较了连续数据(Mann-Whitney U检验)和分类数据(chi(2)检验)。确定治疗前后的显着差异(Wilcoxon试验)。结果:A组的平均通畅时间为4.46个月+/- 3.40,B组为22.29个月+/-8.15。B组的初次通畅率显着提高(100%和85.7%分别为16.7%和0%在6个月和12个月时; P <.001,对数秩检验),再干预率降低(0.29 +/- 0.49对6.17 +/- 1.72,P <.001)。两组的Child-Pugh得分均显着降低。 B组的减少更为持久,且明显更高。结论:扩展的覆有PTFE的覆膜支架显着提高了Budd-Chiari综合征患者的TIPS的通畅率,降低了再干预率并延长了临床改善时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号